Braidwell LP Acquires 176,750 Shares of Glaukos Corporation $GKOS

Braidwell LP raised its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 29.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 780,164 shares of the medical instruments supplier’s stock after buying an additional 176,750 shares during the quarter. Glaukos comprises about 1.9% of Braidwell LP’s holdings, making the stock its 16th largest position. Braidwell LP owned 1.36% of Glaukos worth $63,622,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. AustralianSuper Pty Ltd increased its position in shares of Glaukos by 10.8% in the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock worth $36,685,000 after purchasing an additional 43,750 shares during the last quarter. Riverbridge Partners LLC raised its stake in Glaukos by 41.0% in the third quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after purchasing an additional 165,673 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Glaukos by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after purchasing an additional 27,646 shares during the last quarter. Holocene Advisors LP lifted its position in Glaukos by 40.1% during the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock valued at $108,030,000 after purchasing an additional 299,118 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its stake in Glaukos by 14.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 223,708 shares of the medical instruments supplier’s stock worth $18,243,000 after buying an additional 28,866 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the sale, the director owned 37,449 shares in the company, valued at approximately $4,782,611.79. The trade was a 28.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Aimee S. Weisner sold 15,000 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the sale, the director directly owned 18,806 shares of the company’s stock, valued at approximately $2,207,448.28. This trade represents a 44.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 320,000 shares of company stock valued at $37,202,909 in the last 90 days. 5.80% of the stock is owned by insiders.

Glaukos Stock Performance

Glaukos stock opened at $96.89 on Friday. The firm has a fifty day simple moving average of $114.63 and a two-hundred day simple moving average of $101.25. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $130.23. The company has a market capitalization of $5.63 billion, a PE ratio of -29.72 and a beta of 0.70.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The company had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm’s quarterly revenue was up 35.6% compared to the same quarter last year. During the same period last year, the business posted ($0.40) earnings per share. Research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GKOS shares. BTIG Research reaffirmed a “buy” rating and set a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. Truist Financial increased their target price on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Wells Fargo & Company lifted their price target on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.